<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">32513031</PMID>
        <DateRevised>
            <Year>2021</Year>
            <Month>01</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8352</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>07</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert review of molecular diagnostics</Title>
                <ISOAbbreviation>Expert Rev Mol Diagn</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>715-724</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14737159.2020.1780918</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION">Among the family of fibroblast growth factors (FGFs), FGF19, FGF21, and FGF23 act as circulating hormones and are called endocrine FGFs. FGF19 and FGF21 regulate bile acid and energy homeostasis, respectively, whereas FGF23 regulates vitamin D and phosphate homeostasis. Accumulating evidence suggests that FGF23 plays a critical role in disturbed mineral metabolisms, left ventricular hypertrophy, immunosuppression, inflammation, among others in patients with chronic kidney disease (CKD), highlighting the potential both as a biomarker and a therapeutic target. Several studies have also examined the potential role of FGF19 and FGF21 in CKD patients.</AbstractText>
                <AbstractText Label="AREAS COVERED">In this review, we present a brief overview of the biology of FGF19, FGF21, and FGF23, and summarize recent clinical and experimental studies on the pathophysiological roles of endocrine FGFs, mainly FGF23, in CKD patients.</AbstractText>
                <AbstractText Label="EXPERT OPINION">Among the endocrine FGFs, FGF23 represents the most promising biomarker in CKD patients. If future studies confirm that FGF23 is directly toxic in CKD patients, FGF23 could be regarded as a therapeutic target and its measurement would be valuable if applied in clinical practice. Despite their potentially important roles, the clinical relevance of FGF19 and FGF21 in CKD patients is unclear, and much more studies are required.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kondo</LastName>
                    <ForeName>Yuichiro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interactive Translational Research Center for Kidney Diseases, Tokai University School of Medicine , Isehara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komaba</LastName>
                    <ForeName>Hirotaka</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interactive Translational Research Center for Kidney Diseases, Tokai University School of Medicine , Isehara, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine , Isehara, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Institute of Medical Sciences, Tokai University , Isehara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukagawa</LastName>
                    <ForeName>Masafumi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine , Isehara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Rev Mol Diagn</MedlineTA>
            <NlmUniqueID>101120777</NlmUniqueID>
            <ISSNLinking>1473-7159</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Chronic kidney disease</Keyword>
            <Keyword MajorTopicYN="Y">FGF19</Keyword>
            <Keyword MajorTopicYN="Y">FGF21</Keyword>
            <Keyword MajorTopicYN="Y">FGF23</Keyword>
            <Keyword MajorTopicYN="Y">end-stage kidney disease</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">32513031</ArticleId>
            <ArticleId IdType="doi">10.1080/14737159.2020.1780918</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>